Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial

Journal of Clinical Oncology

Volumn 19, Issue 13, 2001, Pages 3210-3218

  Kelly, K ^a   Crowley, J ^a   Bunn P A , Jr ^a   Presant, C A ^a   Grevstad, P K ^a   Moinpour, C M ^a   Ramsey, S D ^a   Wozniak, A J ^a   Weiss, G R ^a   Moore, D F ^a   Israel, V K ^a   Livingston, R B ^a   Gandara, D R ^a  

^a Operations Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0035397994     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.13.3210     Document Type: Article

References (40)

1. Cancer statistics, 2000
2. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
3. Randomized trial of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
4. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
5. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
6. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861
7. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
8. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial
9. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer
10. Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer
11. Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer
12. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer
13. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: Results of a multicentre, phase II trial
14. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic nonsmall-cell lung cancer
15. Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer
16. Survival determinants in extensive stage non-small-cell lung cancer: The Southwest Oncology Group experience
17. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria
18. The functional assessment of cancer therapy scale: Development and validation of the general measure
19. Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument
20. Nonparametric estimation from incomplete observations
21. A confidence interval for the median survival time
22. Evaluation of survival data and two new rank order statistics arising in its consideration
23. Statistical analysis of survival data
24. Regression models and life-tables
25. Treatment strategies for metastatic non-small-cell lung cancer
26. Phase III study of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
27. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian lung cancer project
28. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
29. Phase III comparative study of high-dose cisplatin (HD-CIS) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small-cell lung cancer (NSCLC)
30. Final results of an EORTC phase III study of paclitaxel versus teniposide, in combination with cisplatin, in advanced NSCLC
31. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group
32. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small-cell lung cancer (NSCLC)
33. Randomized pan-European trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC)
34. A randomized phase III trial of four chemotherapy regimens in advanced non-small-cell lung cancer
35. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study
36. E1594-A randomized phase III trial in metastatic non-small-cell lung cancer (NSCLC): Outcome of PS 2 patients (Pts) - An Eastern Cooperative Group Trial (ECOG)
37. Statistical analysis of quality of life with missing data in cancer clinical trials
38. Missing quality of life data in cancer clinical trials: Serious problems and challenges